Results for this period
Interim period (second quarter)2025年4月1日〜2025年9月30日ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
ヘルスケア事業の医療関連機器製造装置・自動包装機ラインの売上増加、自動車事業の電動駆動関連設備における大口案件の売上計上により、全体の売上高・利益が増加した。
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年4月1日〜2025年9月30日 |
| Net Sales | ¥107,326 million (YoY +6.0%) |
| Operating profit | ¥6,591 million (YoY +7.6%) |
| Ordinary income | ¥6,705 million (YoY +7.9%) |
| Profit attributable to owners of the parent | ¥4,966 million (YoY +15.8%) |
| Net income per share | ¥155.63 |
| Equity ratio | End of the current fiscal period 51 / End of previous period 46.5 |
| Total assets | ¥164,764 million |
| Net assets | ¥84,145 million |
| Cash flows from operating activities | ¥6,297 million |
| Cash flows from investing activities | ¥167 million |
| Cash flows from financing activities | ¥-1,807 million |
| Cash and cash equivalents at end of period | ¥38,188 million |
| Full-year earnings forecast | Net Sales ¥225,000 million (YoY +1.5%) / Operating profit ¥13,200 million (YoY +0.7%) / Ordinary income ¥13,500 million (YoY -0.7%) / Profit attributable to owners of parent ¥9,600 million (YoY +8.6%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥225,000 million / Operating profit Not disclosed → ¥13,200 million / Ordinary income Not disclosed → ¥13,500 million / Profit attributable to owners of parent Not disclosed → ¥9,600 million / Details of revision Upward revision |
| Annual Dividend Forecast | ¥92 → ¥122(+32.6%) |
| Segment revenue | Plant and Energy Business ¥10,624 million (YoY -3.8%), Energy Solutions Business ¥22,285 million (YoY -7.5%), Industrial-Machinery Business ¥12,837 million (YoY -15.4%), Electronics Business ¥22,929 million (YoY -4.3%), Automotive Business ¥23,492 million (YoY +37.2%), Healthcare Business ¥10,925 million (YoY +52.1%), Aerospace and Infrastructure Business ¥4,193 million (YoY +58.7%) |
| Segment profit | Plant and Energy Business ¥719 million (YoY -14.3%), Energy Solutions Business ¥1,279 million (YoY -0.5%), Industrial-Machinery Business ¥200 million (YoY -63.2%), Electronics Business ¥1,231 million (YoY +11.7%), Automotive Business ¥1,652 million (YoY +112.3%), Healthcare Business ¥1,060 million (YoY +39.2%), Aerospace and Infrastructure Business ¥391 million (YoY +161.9%) |
| Depreciation and amortization | ¥556 million |
| Breakdown of extraordinary income (loss) | Gain on sale of investment securities ¥434 million, None - |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Whether applicable No / New Not disclosed / Excluded Not disclosed / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 32,759,200 |
| Treasury Shares at Period-End | 825,819 |
| Factors Behind Changes in Business Performance | ヘルスケア事業の医療関連機器製造装置・自動包装機ラインの売上増加、自動車事業の電動駆動関連設備における大口案件の売上計上により、全体の売上高・利益が増加した。 |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.ヘルスケア事業で医療関連機器製造装置や自動包装機ラインの売上が大幅に増加し、自動車事業で電動駆動関連設備の大口案件を売上計上したため。通期予想は中間期の業績と今後の見通しを考慮して上方修正した。